Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 Stocks That Could Soar This Year

TheMotleyFool 
0 0 01.02.26
2 Stocks That Could Soar This YearPhoto, wide shot, wide-angle lens, soft focus, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
 

In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.

That's precisely what could happen to (NASDAQ: EXEL) and Summit Therapeutics (NASDAQ: SMMT) this year. And the even better news is that there are reasons to consider holding onto these drugmakers' shares even beyond the next 12 months. Let's find out more.

Image source: Getty Images.

Continue reading


Source Fool.com

Exelixis Inc. Stock

€47.85
2.010%
Exelixis Inc. gained 2.010% today.
We see a rather positive sentiment for Exelixis Inc. with 19 Buy predictions and 1 Sell predictions.
However, we have a potential of -8.05% for Exelixis Inc. as the target price of 44 € is below the current price of 47.85 €.
Show more
Like: 0
EXEL
Share

Comments

Not a member yet? Sign up for free!